Recent News

June 3, 2017 Crestone presents Phase 1 data from single and multiple ascending dose clinical trials with CRS3123, at the ASM Microbe Meeting in New Orleans. CRS3123 is a drug candidate in development for the treatment of C. difficile infections.
- https://clinicaltrials.gov/ct2/show/NCT01551004?term=CRS3123&rank=1

- https://clinicaltrials.gov/ct2/show/NCT02106338?term=CRS3123&rank=2

September 8, 2015 Crestone was awarded a Phase II SBIR grant entitled “Optimization and Lead Selection of Novel Antimycobacterial Agents”

July 1, 2015 Crestone receives a multi-stage Contract from NIAID for the preclinical development of its DNA polymerase inhibitor as an oral antibiotic.

July 25, 2014  Crestone was awarded a Phase I SBIR grant entitled “Optimization and Lead Selection of Novel Antimycobacterial Agents”

July 3, 2014  Crestone was awarded an annual renewal of a Phase II SBIR grant entitled “Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic”

May 27, 2014  Crestone’s Vice President of R&D, Dr. Thale Jarvis, was appointed to the Customer Advisory Board of Collaborative Drug Discovery.  
- https://www.collaborativedrug.com/buzz/2014/05/27/collaborative-drug-discovery-cdd-announces-customer-advisory-board-cab-members/

April 30, 2014  Crestone successfully completed work on a two year Bioscience Discovery Evaluation Grant from the State of Colorado Office of Economic Development and Trade.